EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EGFR-Targeted and MMP-Activated Membranolytic Peptides Kill Cancer Cells Specifically In Vitro and Reduce Tumor Growth In Vivo

Arindam Pramanik, Andrew Booth, Dagmara Kobza, William J Brackenbury, Simon D Connell iD, Paul A Beales iD, Thomas A Hughes iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Arindam Pramanik und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Leeds, Leeds LS9 7TF, U.K. Hauptthemen laut MEDLINE: ErbB Receptors, Peptides, Matrix Metalloproteinase 2, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Engineering and Physical Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsPeptidesMatrix Metalloproteinase 2Antineoplastic AgentsBreast NeoplasmsHumansAnimalsFemaleMiceCell Line, TumorXenograft Model Antitumor AssaysApoptosisMice, NudeCell Proliferation

Stichwörter der Autor:innen

EGFRcancer targetingmatrix metalloproteinasesmembranolyticprecision medicine

Substanzen

ErbB ReceptorsPeptidesMatrix Metalloproteinase 2EGFR protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • School of Medicine, University of Leeds, Leeds LS9 7TF, U.K.
  • Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh 201303, India.
  • School of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, U.K.
  • Jack Birch Cancer Research Unit, York Biomedical Research Institute, Department of Biology, University of York, York YO10 5DD, U.K.
  • School of Physics and Astronomy and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, U.K.
  • School of Science, Technology and Health, York St John University, York YO31 7EX, U.K.

ORCID-Profile: Simon D Connell, Paul A Beales, Thomas A Hughes

Förderung

  • Engineering and Physical Sciences Research Council

Zitieren

APA

Pramanik, A., Booth, A., Kobza, D., Brackenbury, W. J., Connell, S. D., Beales, P. A., & Hughes, T. A. (2026). EGFR-Targeted and MMP-Activated Membranolytic Peptides Kill Cancer Cells Specifically In Vitro and Reduce Tumor Growth In Vivo. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01774

Vancouver

Pramanik A, Booth A, Kobza D, Brackenbury WJ, Connell SD, Beales PA, et al. EGFR-Targeted and MMP-Activated Membranolytic Peptides Kill Cancer Cells Specifically In Vitro and Reduce Tumor Growth In Vivo. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01774

BibTeX
@article{Pramanik2026,
  author = {Pramanik, Arindam and Booth, Andrew and Kobza, Dagmara and Brackenbury, William J and Connell, Simon D and Beales, Paul A and Hughes, Thomas A},
  title = {EGFR-Targeted and MMP-Activated Membranolytic Peptides Kill Cancer Cells Specifically In Vitro and Reduce Tumor Growth In Vivo},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01774}
}
Kostenlos starten →